These results indicates that PRMT5 promotes cell cycle progression, and combination of PRMT5 inhibitors with cyclin‐dependent kinase (CDK) inhibitors may provide therapeutic value in pancreatic cancer. The gene discussed is PRMT5; the disease is familial pancreatic carcinoma.